1 |
YANG Y, MENG L, WU S, et al.. LIGHT deficiency aggravates cisplatin-induced acute kidney injury by upregulating mitochondrial apoptosis[J/OL]. Int. Immunopharmacol., 2020, 89: 106999[2022-11-20]. .
|
2 |
HU J, GU W, MA N, et al.. Leonurine alleviates ferroptosis in cisplatin‐induced acute kidney injury by activating the Nrf2 signalling pathway[J]. Br. J. Pharmacol., 2022, 179(15): 3991-4009.
|
3 |
FANG C, LOU D, ZHOU L, et al.. Natural products: potential treatments for cisplatin-induced nephrotoxicity[J]. Acta. pharmacol. Sin., 2021, 42(12): 1951-1969.
|
4 |
孟利,杨雁,张克勤,等.Fgl2在顺铂诱导的小鼠急性肾损伤中的作用及机制研究[J].免疫学杂志,2021,37(2):93-99.
|
5 |
张术姣,谭小月,张勉之.丹参提取物对顺铂诱导小鼠急性肾损伤的影响及机制研究[J].中华中医药杂志,2021,36(12):7324-7328.
|
6 |
WANG B, HUANG C, LIU L, et al.. Pim1 kinase inhibitors exert anti-cancer activity against HER2-positive breast cancer cells through downregulation of HER2[J/OL]. Front. Pharmacol., 2021, 12: 614673[2022-11-22]. .
|
7 |
EBEID D E, FIROUZI F, ESQUER C Y, et al.. PIM1 promotes survival of cardiomyocytes by upregulating c-Kit protein expression[J/OL]. Cells, 2020, 9(9): 2001[2022-11-21]. .
|
8 |
ZHU H, WANG X, SUN Y, et al.. Pim1 overexpression prevents apoptosis in cardiomyocytes after exposure to hypoxia and oxidative stress via upregulating cell autophagy[J]. Cell Physiol. Biochem., 2018, 49(6): 2138-2150.
|
9 |
ANDREUCCI M, FAGA T, PISANI A, et al.. Quercetin protects against radiocontrast medium toxicity in human renal proximal tubular cells[J]. J. Cell Physiol., 2018, 233(5): 4116-4125.
|
10 |
SEIFERT C, BALZ E, HERZOG S, et al.. PIM1 inhibition affects glioblastoma stem cell behavior and kills glioblastoma stem-like cells[J/OL]. Int. J. Mol. Sci., 2021, 22(20): 11126[2022-11-22]. .
|
11 |
WU J, CHU E, KANG Y. PIM kinases in multiple myeloma[J/OL]. Cancers, 2021, 13(17): 4304[2022-11-22]. .
|
12 |
YUAN Y, WANG C, ZHUANG X, et al.. PIM1 promotes hepatic conversion by suppressing reprogramming-induced ferroptosis and cell cycle arrest[J]. Nat. Commun., 2022, 13(1): 5237-5356.
|
13 |
CHAUHAN S S, TOTH R K, JENSEN C C, et al.. PIM kinases alter mitochondrial dynamics and chemosensitivity in lung cancer[J]. Oncogene, 2020, 39(12): 2597-2611.
|
14 |
ZHAO B, LIU L, MAO J, et al.. PIM1 mediates epithelial-mesenchymal transition by targeting Smads and c-Myc in the nucleus and potentiates clear-cell renal-cell carcinoma oncogenesis[J/OL]. Cell Death. Dis., 2018, 9(3): 307[2022-11-22]. .
|
15 |
李侃,肖啸,周森,等.自噬途径在急性肾损伤中的作用及靶向治疗策略研究进展[J].中国综合临床,2022,38(5):466-470.
|
16 |
熊哲学,李凝旭,唐明娟.钠-葡萄糖协同转运蛋白2抑制剂对足细胞自噬影响及其肾脏保护机制的研究进展[J].中国糖尿病杂志,2022,30(7):554-557.
|
17 |
金丽霞,张晓东,潘超,等.中医药调控线粒体自噬防治慢性肾脏病的研究进展[J].中国中药杂志,2022,47(13):3432-3438.
|
18 |
KLIONSKY D J, PETRONI G, AMARAVADI R K, et al.. Autophagy in major human diseases[J/OL]. EMBO J., 2021, 40(19): e108863[2022-12-07]. .
|
19 |
KONG L, DENG J, ZHOU X, et al.. Sitagliptin activates the p62-Keap1-Nrf2 signalling pathway to alleviate oxidative stress and excessive autophagy in severe acute pancreatitis-related acute lung injury[J/OL]. Cell Death. Dis., 2021, 12(10): 928[2022-12-07]. .
|
20 |
JIANG K, XU Y, WANG D, et al.. Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis[J]. Protein Cell, 2022, 13(5): 336-359.
|
21 |
王珍,杨洛,廖敏,等.mTOR信号通路在糖尿病肾病发病机制中的研究进展[J].生物技术进展,2021,11(3):316-321.
|
22 |
XU J, SHAN X, CHEN C, et al.. Tangshenning attenuates high glucose-induced podocyte injury via restoring autophagy activity through inhibiting mTORC1 activation[J/OL]. J. Diabetes. Res., 2022, 2022: 1610416[2022-12-08]. .
|
23 |
TAN X, ZHU H, TAO Q, et al.. FGF10 protects against renal ischemia/reperfusion injury by regulating autophagy and inflammatory signaling[J/OL]. Front. Genet., 2018, 9: 556[2022-11-22]. .
|
24 |
ZHOU J, FAN Y, ZHONG J, et al.. TAK1 mediates excessive autophagy via p38 and ERK in cisplatin‐induced acute kidney injury[J]. J. Cell Mol. Med., 2018, 22(5): 2908-2921.
|
25 |
ZHOU L, ZHANG L, ZHANG Y, et al.. PINK1 deficiency ameliorates cisplatin-induced acute kidney injury in rats[J/OL]. Front. Physiol., 2019, 10: 1225[2022-11-23]. .
|